期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Targeting DNA repair pathways to overcome cancer drug resistance 被引量:1
1
作者 robert c.a.m.van waardenburg Eddy S.Yang 《Cancer Drug Resistance》 2021年第4期837-841,共5页
DNA damage response and DNA repair pathways are evolutionarily conserved from prokaryotes to eukaryotes to protect the host from genomic instability.Dysregulation of proteins involved in these pathways in mammalian ce... DNA damage response and DNA repair pathways are evolutionarily conserved from prokaryotes to eukaryotes to protect the host from genomic instability.Dysregulation of proteins involved in these pathways in mammalian cells increases genomic alterations leading to genomic instability,a well-established hallmark of cancer^([1,2]).However,our understanding of the signaling pathways to repair DNA damage in cancers has grown exponentially over the last decades. 展开更多
关键词 DAMAGE alterations CANCER
原文传递
Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts 被引量:1
2
作者 Evan J.Brettrager robert c.a.m.van waardenburg 《Cancer Drug Resistance》 2019年第4期1153-1163,共11页
Our genomic DNA is under constant assault from endogenous and exogenous sources,which needs to be resolved to maintain cellular homeostasis.The eukaryotic DNA repair enzyme Tyrosyl-DNA phosphodiesterase I(Tdp1)catalyz... Our genomic DNA is under constant assault from endogenous and exogenous sources,which needs to be resolved to maintain cellular homeostasis.The eukaryotic DNA repair enzyme Tyrosyl-DNA phosphodiesterase I(Tdp1)catalyzes the hydrolysis of phosphodiester bonds that covalently link adducts to DNA-ends.Tdp1 utilizes two catalytic histidines to resolve a growing list of DNA-adducts.These DNA-adducts can be divided into two groups:small adducts,including oxidized nucleotides,RNA,and non-canonical nucleoside analogs,and large adducts,such as(drug-stabilized)topoisomerase-DNA covalent complexes or failed Schiff base reactions as occur between PARP1 and DNA.Many Tdp1 substrates are generated by chemotherapeutics linking Tdp1 to cancer drug resistance,making a compelling argument to develop small molecules that target Tdp1 as potential novel therapeutic agents.Tdp1’s unique catalytic cycle,which is centered on the formation of Tdp1-DNA covalent reaction intermediate,allows for two principally different targeting strategies:(1)catalytic inhibition of Tdp1 catalysis to prevent Tdp1-mediated repair of DNA-adducts that enhances the effectivity of chemotherapeutics;and(2)poisoning of Tdp1 by stabilization of the Tdp1-DNA covalent reaction intermediate,which would increase the half-life of a potentially toxic DNA-adduct by preventing its resolution,analogous to topoisomerase targeted poisons such as topotecan or etoposide.The catalytic Tdp1 mutant that forms the molecular basis of the autosomal recessive neurodegenerative disease spinocerebellar ataxia with axonal neuropathy best illustrates this concept;however,no small molecules have been reported for this strategy.Herein,we concisely discuss the development of Tdp1 catalytic inhibitors and their results. 展开更多
关键词 Tdp1 small molecules DNA topoisomerases CAMPTOTHECINS oxidative DNA damage DNA adducts ETOPOSIDE chain terminating nucleotides/nucleoside analogs DNA metabolism drug development
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部